<- All drugs

Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Mazdutide

INVESTIGATIONAL

GLP-1/glucagon dual agonist

graded findings

effect domains

Evidence spread

High evidence 0Moderate evidence 5Low evidence 3Very low evidence 4

Mazdutide is shown as an investigational or pipeline evidence record. Findings describe what studies and reports observed; they do not endorse use or establish personal suitability.

Mazdutide INVESTIGATIONAL

Weight change Decrease

Moderate evidence

In the registrational Chinese phase-3, the GLP-1/glucagon dual agonist mazdutide produced 11-14% weight loss with low (~1%) discontinuation.

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source

PopulationGLORY-1 (NCT05607680): 610 Chinese adults with obesity or overweight (BMI >=28, or 24-<28 plus a weight-related condition), mazdutide 4/6 mg vs placebo 1:1:1; 48-week phase-3 randomised double-blind placebo-controlled RCT.

FundingInnovent Biologics

Scope limitsChina-only population (BMI thresholds 28 / 24+comorbidity differ from Western cut-offs) - GENERALISABILITY caveat; placebo-controlled, not head-to-head.

Mazdutide INVESTIGATIONAL

Weight change Decrease

Moderate evidence

Phase 3 GLORY-1 confirmed substantial weight loss vs placebo at 48 wk

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source

PopulationChinese overweight/obese with ≥1 comorbidity (n=610), phase 3, 48 wk, RCT (4/6 mg vs placebo); NEJM 10.1056/NEJMoa2411528

FundingInnovent Biologics

Scope limitsNEJM DOI from journal listing; exact figures from press release/secondary — flag magnitude as press-derived (Re-pointed 2026-06-23 from duplicate press/registry row to published GLORY-1 source PMID40421736; press-derived caveat retained.)

Comparatorsplacebo

Mazdutide INVESTIGATIONAL

Weight change Decrease

Low evidence

High-dose mazdutide produced marked early weight loss vs placebo in Chinese overweight/obese adults

Ji L et al. EClinicalMedicine 2022;54:101691 Source

PopulationChinese overweight/obese adults (n=24), phase 1b MAD, 12-16 wk, RCT placebo-controlled (NCT04440345)

Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)

Scope limitssmall sample (N~24)

Comparatorsplacebo

Mazdutide INVESTIGATIONAL

Weight change Decrease

Very low evidence

Mazdutide (IBI362 / LY3305677; Innovent, licensed from Lilly) is a GLP-1/glucagon dual agonist (mammalian oxyntomodulin analogue) developed largely in Chinese...

Ji et al., GLORY-1 phase 3, NEJM 2025 (Innovent); ADA 2024; Nat Commun 2023 phase 2 Source

Full findingMazdutide (IBI362 / LY3305677; Innovent, licensed from Lilly) is a GLP-1/glucagon dual agonist (mammalian oxyntomodulin analogue) developed largely in Chinese populations. In phase 3 GLORY-1 (overweight/obesity, no T2D), mean weight change at 48 weeks was -11.00% (4 mg) and -14.01% (6 mg) vs +0.30% placebo (primary endpoint week 32: -10.09% / -12.55% vs +0.45% placebo); 49.5% of the 6 mg group achieved >=15% weight loss vs 2.0% placebo. Phase 2 with a 9 mg dose showed ~20% weight loss at ~48 weeks.

PopulationGLORY-1: 610 Chinese adults overweight (BMI>=24 + comorbidity) or obesity (BMI>=28), once-weekly s.c. 4/6 mg vs placebo, 48 wk; phase 2 (n~248) doses to 9 mg

Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)

Scope limitsno outcome data yet (ongoing)

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

Glycaemic control Decrease

Moderate evidence

In a phase 3 trial in Chinese adults with T2D, both mazdutide doses were non-inferior and superior to dulaglutide 1.5 mg for HbA1c reduction at 28 weeks (head-to-head).

Guo L et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature ... Source

Population731 Chinese adults with T2D on background oral antidiabetics, randomised 1:1:1; 28-week phase 3 RCT

Fundingindustry - Innovent Biologics (mazdutide licensed from Eli Lilly in China)

Scope limitsComparator dulaglutide at 1.5 mg (not max 4.5 mg). Chinese-only population may limit generalisability.

Comparatorsdulaglutide 1.5 mg

Mazdutide INVESTIGATIONAL

Glycaemic control Not directional

Very low evidence

DREAMS-3, the first head-to-head mazdutide-vs-semaglutide trial in Chinese adults with T2D + obesity, is designed but results pending (registry/protocol only).

Luo Y et al. Mazdutide versus Semaglutide for T2D and obesity: rationale, design and base... Source

Population349 Chinese adults with T2D (≤10 y) and obesity (BMI ≥28); 32-week open-label active-controlled phase 3 RCT; comparator semaglutide 1 mg

Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)

Scope limitsopen-label (unblinded)

Comparatorssemaglutide 1 mg

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

Body composition Decrease

Very low evidence

GLORY-1/GLORY-2 phase 3 (Chinese adults with obesity): mazdutide met key secondary endpoints including reduced waist circumference and liver-fat content; dual...

Innovent / Eli Lilly, GLORY-1 and GLORY-2 phase 3 (mazdutide) Source

Full findingGLORY-1/GLORY-2 phase 3 (Chinese adults with obesity): mazdutide met key secondary endpoints including reduced waist circumference and liver-fat content; dual GCG/GLP-1 mechanism described as potentially yielding more favourable fat-vs-muscle partition, but no quantified DXA fat/lean split located.

PopulationGLORY-1 (n=610) and GLORY-2 phase 3 RCTs in Chinese adults with obesity; 48-60 weeks

Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)

Scope limitsGAP: quantified DXA fat/lean partition for mazdutide not found in this sweep; waist circumference and liver fat are the available body-composition-adjacent readouts. Flagged for follow-up against the published GLORY papers.

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

hepatic-mash Not directional

Very low evidence

Mazdutide (IBI362; Innovent/Lilly, GLP-1/glucagon dual) has NO published dedicated human MASH histology trial. Human liver benefit is so far described within...

Gan L, Duan L, Zheng X. Mazdutide ameliorates MASLD (rodent). Pharmaceuticals 2026;19(3):... Source

Full findingMazdutide (IBI362; Innovent/Lilly, GLP-1/glucagon dual) has NO published dedicated human MASH histology trial. Human liver benefit is so far described within obesity/T2D programmes; the histology evidence is rodent. A dedicated clinical MASLD/MASH programme is referenced in reviews but not yet published.

PopulationPreclinical: high-fat-diet mouse MASLD + FFA hepatocytes (PMID 41901218; rodent MRI PMID 40828048). Human MASH histology trial: not yet published.

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Scope limitsanimal data; human relevance uncertain

Comparatorssemaglutide (preclinical comparator)

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

Blood pressure Decrease

Moderate evidence

Mazdutide reduced systolic blood pressure vs placebo (GLORY-1)

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source

PopulationChinese overweight/obese (n=610), phase 3 GLORY-1, 48 wk

FundingInnovent Biologics

Scope limitsBP magnitude press-derived; flag unconfirmed pending full-text (Re-pointed 2026-06-23 from duplicate press/registry row to published GLORY-1 source PMID40421736; press-derived caveat retained.)

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

Energy expenditure and thermogenesis Increase

Low evidence

Glucagon-receptor arm proposed to increase energy expenditure and improve hepatic fat metabolism (mammalian OXM analogue)

Sidrak WR et al. Indian J Endocrinol Metab 2024;28:445-460 Source

PopulationMechanistic / review framing

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Scope limitsEE claim mechanistic; cross-ref cognition/EE preclinical PMID:40479843

Comparatorsdulaglutide (preclinical)

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

Lipids and lipoproteins Decrease

Moderate evidence

Reduced total cholesterol, triglycerides, LDL-C and serum uric acid

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source

PopulationChinese overweight/obese (n=610), phase 3, 48 wk

FundingInnovent Biologics

Scope limitsMagnitude unconfirmed Magnitude press-derived (re-pointed 2026-06-23 from the duplicate press/registry GLORY-1 row to the genuine published source PMID40421736; figures pending full-text confirmation).

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Mazdutide INVESTIGATIONAL

Gastrointestinal tolerability Increase

Low evidence

Mild-to-moderate GI TEAEs; no serious AEs in phase 1b

Ji L et al. EClinicalMedicine 2022;54:101691 Source

PopulationChinese overweight/obese (n=24), phase 1b

Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)

Scope limitssmall sample (N~24)

Comparatorsplacebo